Larazotide
Larazotide: Research Overview
Larazotide is a synthetic octapeptide investigated as a zonulin antagonist in intestinal epithelial barrier research. This page is a reference summary of what the compound is, what mechanism it is studied for, and what published investigation exists. It is written for laboratory personnel and is not a use guide.
All RawBiotix compounds are supplied for laboratory research use only. Not for human consumption, therapeutic use, or diagnostic use.
What Larazotide Is
Larazotide, also written as larazotide acetate, is a synthetic peptide eight amino acids in length. It is not derived from a biological extract. It is assembled by solid phase synthesis and characterised analytically before release.
- Classification: Synthetic octapeptide, zonulin antagonist
- Sequence: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly
- CAS number: 881851-50-9
- Molecular formula: C32H55N9O10
- Molecular weight: 725.8 Da
- Catalog format at RawBiotix: oral research format, 60 capsules at 500mcg
Larazotide is frequently searched alongside the term N-acetyl larazotide. These are not the same molecule. N-acetyl larazotide carries an acetyl group at the N terminus, which changes the compound and its analytical profile. RawBiotix supplies larazotide acetate as specified above and does not supply the N-acetylated variant. Anything sold under either name should be confirmed against a certificate of analysis rather than against a product title.
The Mechanism Under Investigation
The intestinal epithelium is a single cell layer whose cells are joined by protein complexes called tight junctions. Those junctions regulate paracellular transport, meaning what is able to pass between cells rather than through them. Zonulin is a signalling protein that modulates the assembly of those junctions.
Larazotide is studied as a zonulin antagonist. Research interest centres on whether occupying that pathway alters tight junction assembly and therefore paracellular permeability in epithelial models. The specific protein complexes examined in this work include occludin and the claudin family.
Common experimental readouts in this area include transepithelial electrical resistance, tracer flux across a monolayer, and immunostaining of junctional proteins. These are in vitro measurements taken from cell culture models, not from people.
The Published Research Record
Larazotide has been examined in celiac disease, IBS-D, and barrier dysfunction experimental systems, with a documented published record across multiple clinical-phase and preclinical investigations. That record is unusually substantial for a compound in this category, which is a large part of why it is of interest to researchers working on epithelial barrier models.
The existence of a published record is not a statement about outcome, safety, or effect. Compounds are investigated for many reasons and investigation is not endorsement. RawBiotix makes no claim about what larazotide does in any organism and supplies it for laboratory research only.
Related Compounds in Barrier and Epithelial Research
Researchers working on epithelial barrier models frequently work with more than one compound in parallel. The following are supplied by RawBiotix and appear in adjacent research areas.
- KPV 500mcg (30 Capsules), a tripeptide examined in pathway analysis relating to epithelial barrier response.
- BPC-157 10mg, examined in tissue and cellular structural research models.
- LL-37 10mg, a cathelicidin fragment examined in immune and cytokine signalling models.
Format, Handling and Storage
RawBiotix supplies larazotide in an oral research format, 60 capsules at a 500mcg catalog strength. There is no vial and there is nothing to reconstitute. Material in this format is intended for controlled laboratory handling and analytical preparation only.
Handle sealed units with standard laboratory personal protective equipment. Keep the container tightly closed between uses. Protect the material from heat, moisture, and cross-contamination. Store in a cool, dry environment away from heat, moisture, and direct light.
RawBiotix does not publish preparation, quantity, or administration information for any compound. That information would only be relevant to use in an organism, which is outside what these products are supplied for.
Sourcing and Verification
RawBiotix research compounds are sourced through U.S.-based supply and verified through independent analytical testing. Minimum 98% purity. Certificates of Analysis available upon request.
A certificate of analysis is the only document that establishes what is actually in a container. Purity claimed on a product page, including on this one, is a specification rather than a measurement of the specific unit shipped. Researchers should request the certificate for the lot they receive.
Common Questions
Is larazotide a peptide? Yes. It is a synthetic octapeptide, meaning a chain of eight amino acids assembled synthetically rather than isolated from a biological source.
Is larazotide the same as N-acetyl larazotide? No. See the section above. The N-acetylated compound is a different molecule.
Does RawBiotix ship outside the United States? No. RawBiotix ships within the United States only. Searches for larazotide in other territories will not be served by this catalog.
What quantity should be used? RawBiotix does not provide that information. These compounds are supplied for laboratory research use only and are not for human consumption, therapeutic use, or diagnostic use.
Where can the product page be found? Larazotide 500mcg (60 Capsules).
Disclaimer
This product is not a drug, food, cosmetic, or dietary supplement and has not been reviewed or approved by the FDA. It is intended strictly for in vitro research conducted by qualified professionals. Use in humans or animals is not permitted and may be subject to federal, state, or local regulations, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic use is implied or authorized. The purchaser is solely responsible for ensuring compliance with all applicable laws and regulations.